A kind of maleimide-modified hydroxychloroquine and its preparation method and application

The combination of maleimide modified hydroxychloroquine and manganese porphyrin-based metal organic framework nanoreactors has solved the side effects and pharmacokinetic problems of hydroxychloroquine in autophagy inhibition, significantly improving the efficiency of autophagy blockade and Tumor treatment effect.

CN117304168BActive Publication Date: 2024-12-06THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311248895.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-26
Publication Date
2024-12-06
Estimated Expiration
2043-09-26

AI Technical Summary

Technical Problem

Hydroxychloroquine has side effects as a drug blocking autophagy, and its pharmacokinetic characteristics are unclear, resulting in poor inhibition of autophagy, limiting its application in autoimmune diseases and tumor treatment.

Method used

hydroxychloroquine (MHCQ) is modified by maleimide, and the classic click reaction of maleimide and thiol is used to improve the efficiency of autophagy blocking and load it into a manganese porphyrin-based metal organic frame nanoreactor. Achieve efficient tumor cell apoptosis and autophagy inhibition.

Benefits of technology

It significantly enhances the efficiency of autophagy blockade, promotes apoptosis, improves the inhibitory effect on tumor cells, and improves the bioavailability and safety of the drug through the design of nanocarriers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117304168B_ABST
    Figure CN117304168B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of medicine, and in particular to a maleimide-modified hydroxychloroquine and a preparation method and application thereof, so as to further enhance the efficacy of hydroxychloroquine and enhance the efficiency of its autophagy blocking. The maleimide-modified hydroxychloroquine provided by the present invention has a structure as shown below: #imgabs0#. The compound is synthesized for the first time by the inventor of the present application. The inventor applies the ingenious design based on click chemistry to enhance the efficacy of autophagy inhibition, and pioneeringly proposes a new concept of using Mal-SH reaction to achieve autophagy capture, which greatly improves the efficiency of autophagy blocking. The inventor's first study on Mal-modified hydroxychloroquine not only provides a new compound, but also provides a new choice for the preparation of drugs for the treatment of various diseases, and also provides a forward-looking idea and a solid research foundation for biomedical applications based on click chemistry.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of medicine, and in particular to maleimide-modified hydroxychloroquine and a preparation method and application thereof. Background Art

[0002] Hydroxychloroquine (HCQ) is an antimalarial drug that is widely used to treat autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. In recent years, studies have found that HCQ also has the effect of inhibiting autophagy, so it has attracted much attention as a drug that blocks autophagy. However, there are also many problems with HCQ as a drug that blocks autophagy. First, HCQ has significant side effects, and long-term use may cause damage to organs such as the retina, liver, and kidneys. Second, the pharmacokinetic characteristics of HCQ are still unclear, and its blood concentration and duration of action are difficult to control. The effect of inhibiting autophagy is still limited by the characteristics of fast metabolism and low selectivity of small molecule inhibitors, and the autophagy inhibition effect is poor.

[0003] Hydroxychloroquine has broad application prospects as a drug that blocks autophagy, especially in the fields of autoimmune diseases and tumor treatment. However, its side effects and pharmacokinetic characteristics limit its clinical application. Therefore, in the future, in-depth research is still needed on the mechanism of action, pharmacokinetic characteristics, finding more specific drug targets, and optimizing medication regimens of hydroxychloroquine to further improve the efficacy of hydroxychloroquine and enhance the efficiency of autophagy blocking, so as to achieve more effective treatment and better patient benefits. Summary of the invention

[0004] The technical problem to be solved by the present invention is to provide a maleimide-modified hydroxychloroquine to further improve the efficacy of hydroxychloroquine and enhance its autophagy blocking efficiency.

[0005] The basic scheme provided by the present invention is: a maleimide-modified hydroxychloroquine, the compound having the structure shown below:

[0006] .

[0007] The working principle and advantages of the present invention are:

[0008] The inventors found that the classic click reaction between maleimide (Mal) and thiol (-SH) is highly efficient and specific, and the exposed thiol on the protein can bind to the maleimide group with high sensitivity. Therefore, this application has innovatively proposed a new concept, that is, to use the Mal-SH reaction to achieve autophagy capture. Specifically, the inventors synthesized a new compound for the first time, namely Mal-modified hydroxychloroquine ( MThe inventors' first study on Mal-modified hydroxychloroquine not only provides a new compound and a new option for the preparation of drugs for the treatment of various diseases, but also provides a forward-looking idea and a solid research foundation for biomedical applications based on click chemistry.

[0009] The present invention also provides a method for preparing maleimide-modified hydroxychloroquine, comprising the following steps:

[0010] Hydroxychloroquine is dissolved in N,N-dimethylformamide, and then the solution is mixed with 3-maleimide propionic acid, 4-dimethylaminopyridine, 1-hydroxybenzotriazole and carbodiimide, and then stirred and dried to obtain maleimide-modified hydroxychloroquine. M HCQ, and finally purified.

[0011] Preferably, the stirring time is 6-8 hours.

[0012] Preferably, purification is performed using high performance liquid chromatography.

[0013] Preferably, the mass ratio of hydroxychloroquine to 3-maleimidopropionic acid is 4:2405.

[0014] The maleimide-modified hydroxychloroquine of the present invention is used as a drug for preparing a tumor treatment drug. M HCQ significantly enhances the efficiency of autophagy blocking and can further promote cell apoptosis, thereby inhibiting the growth of tumor cells and can be used as a tumor treatment drug.

[0015] Preferably, the tumor is breast cancer.

[0016] Preferably, maleimide-modified hydroxychloroquine is loaded on a carrier. M HCQ is loaded on a carrier for use, which can well protect the drug molecules and is also conducive to the release and control of the drug, further improving M Bioavailability of HCQ.

[0017] Preferably, the carrier is a manganese porphyrin-based metal organic framework. The manganese porphyrin-based metal organic framework has a mesoporous structure and can achieve M Efficient loading of HCQ.

[0018] Preferably, the manganese porphyrin-based metal organic framework is spindle-shaped. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 for M Characterization of HCQ, where (a) is M Mass spectrometry results of HCQ; (b)M HCQ HPLC results; (c) HCQ and M UV-visible spectrum of HCQ; (d) M Proton NMR spectrum of HCQ ( Figure 1 d The upper left corner is M Chemical structure of HCQ).

[0020] Figure 2 Characterization of MnTCPP MOF, where (a) is the transmission electron microscopy of MnTCPP MOF; (b) is the scanning electron microscopy of MnTCPP MOF; (c) is the specific surface area of ​​MnTCPP MOF; (d) is the pore size of MnTCPP MOF; (e) is M Standard concentration curve of HCQ.

[0021] Figure 3 For Lip@M- M H characterization, where (a) is Lip@M- M H; (b) elemental analysis; (c) XRD; (d) UV-visible spectrum; (e) particle size on the left and potential on the right; (f) particle size stability; (g) Lip@M- M H and Lip@M- M Drug release behavior of H+US; (h) is the transmission electron microscopy after drug release; (i) is the scanning electron microscopy after the lipid membrane was dissolved with phosphate buffer and mixed with MnTCPP.

[0022] Figure 4 Figure 2 shows the sonodynamic performance of the nanoreactor and the cell phagocytosis reaction, where (a) is the ESR spectra of PBS, MnTCPP and Lip@M with or without ultrasonic irradiation; (b) is the UV-visible absorption spectra of the degradation of methylene blue mediated by MnTCPP and Lip@M with or without ultrasonic irradiation; (c) and (d) are the concentration-dependent and time-dependent SOSG probes showing the production of Lip@M, respectively. 1 O2.

[0023] Figure 5 Figure 2 shows the detection of in situ click reaction-enhanced autophagy inhibition, where (a) is a schematic diagram of in situ protein capture mediated by Mal-SH click reaction; (b) is a schematic diagram of cell fragment preparation and transwell chamber simulated protein capture; (c) is M Zeta potential of HCQ and OVA, and the relationship between HCQ and M Zeta potential of OVA after HCQ incubation; (d) M Zeta potential of HCQ and OVA, and Lip@M- M H and Lip@M-M Zeta potential of OVA after H + US incubation; (e) Protein quantification in the upper chamber of transwell after different treatments; (f) Protein quantification in the lower chamber of transwell after different treatments; (g) Western blot detection of the expression of LC3B-II / I, p62, and Beclin-1 in different groups; (h), (i) and (j) are quantitative analysis of the relative gray value of LC3B-II / I, p62, and Beclin-1, respectively; (k) is the immunofluorescence image of LC3B in 4T1 cells after different treatments; (l) is the immunofluorescence image of Lip@M- M Biological transmission electron microscopy images of 4T1 cells treated with H + US.

[0024] Figure 6 The biosafety and cytotoxicity tests of different nanoreactors are shown in Figure 1. (a) Lip@M- M Figure 2 shows the cell survival rate of cells after co-incubation with 4T1 and HUVEC for 24 hours; (b) shows the cell survival rate of cells after co-incubation with 4T1 and HUVEC containing MnTCPP at different concentrations for 24 hours; (c) shows the relative cell survival rate after co-incubation with 4T1 cells at different concentrations of different reactors; (d) and (e) show the level of cell apoptosis after different treatments determined by flow cytometry and the corresponding quantitative analysis; (f) shows the fluorescence images of 4T1 cells after different treatments stained with PI and calcein AM, respectively.

[0025] Figure 7 Nanoreactor Lip@M- M In vivo biosafety of H, where (a) is PBS, deionized water, MnTCPP, M-MH, Lip@M- M Evaluation of the hemolytic effect of cells after H treatment; (b)-(d) are intravenous administration of Lip@M- M Blood biochemical test results of Kunming mice killed at different time intervals after H; (e)-(m) are the results of intravenous administration of Lip@M- M Blood routine examination results of mice at different time intervals after H, n = 6; (n) is the result of intravenous administration of Lip@M- M H&E staining images of the heart, liver, spleen, lung, and kidney of mice killed at different time intervals after H. DETAILED DESCRIPTION

[0026] The inventors found that the classic click reaction between maleimide (Mal) and thiol (-SH) is highly efficient and specific. Tumor-derived proteins are released from cell debris under the stimulation of sound dynamic therapy (SDT). The thiol exposed on the damaged protein can bind to the maleimide group with high sensitivity. Therefore, this application has innovatively proposed a new concept, that is, to achieve autophagy capture by using the Mal-SH reaction in situ in the tumor. Specifically, the inventors synthesized Mal-modified hydroxychloroquine ( M HCQ), when SDT is implemented, tumor cells are killed to produce cell or protein fragments, and then maleimide-modified hydroxychloroquine cells covalently bind to the -SH group of the damaged protein through the Mal-SH reaction and anchor to the protein fragments. Subsequently, due to the inherent self-protection mechanism of cancer cells, the autophagic process is rapidly activated. The autophagosome then encapsulates the damaged protein and engulfs the protein-anchored hydroxychloroquine, allowing the autophagosome to actively contact the hydroxychloroquine with anti-autophagic function. Finally, hydroxychloroquine consumes hydrogen ions and changes the internal pH of proteolytic enzymes during the fusion process of autophagosomes and lysosomes, thereby blocking the autophagic flux and significantly enhancing the efficiency of autophagy blocking.

[0027] The inventors of this application first applied the ingenious design based on click chemistry to enhance the efficacy of autophagy inhibition, and pioneered the new concept of using the Mal-SH reaction in situ in the tumor to achieve autophagy capture, and synthesized Mal-modified hydroxychloroquine for the first time. M HCQ greatly improves the efficiency of autophagy blocking.

[0028] The following is a further detailed description through specific implementation methods:

[0029] Example 1: Mal-modified hydroxychloroquine M HCQ

[0030] M The preparation method of HCQ comprises the following steps:

[0031] Hydroxychloroquine was dissolved in 40 ml of N,N-dimethylformamide, and then the solution was mixed with 3-maleimide propionic acid, 170 g of 4-dimethylaminopyridine, 270 g of 1-hydroxybenzotriazole and 5 ml of carbodiimide (the mass ratio of hydroxychloroquine to 3-maleimide propionic acid was 4:2405, in this embodiment, hydroxychloroquine was 0.8 g, and 3-maleimide propionic acid was 481 g), and magnetic stirring was carried out at room temperature for 6-8 hours (the stirring time in this embodiment was 6 hours), and orange-red crystals of maleimide-modified hydroxychloroquine were obtained after spin drying. M HCQ was finally purified by high performance liquid chromatography.

[0032] Example 2: Lip@M- M H (Lip@M- M H is lipid membrane@MnTCPP MOF- M HCQ is the abbreviation of lipid membrane, Lip is the abbreviation of lipid membrane, MnTCPP MOF is the abbreviation of manganese porphyrin-based metal organic framework, M H is Mal-modified hydroxychloroquine M HCQ abbreviation)

[0033] This application will M HCQ is loaded on a carrier for application. In this embodiment, manganese porphyrin-based metal organic framework is used as the carrier to achieve M HCQ's efficient load, well protected M HCQ is also beneficial M The release and control of HCQ further improves its bioavailability. M To prevent the non-specific binding of HCQ to non-targeted proteins, the inventors coated the outer surface of the manganese porphyrin-based metal organic framework with a PEGylated lipid membrane. M The Mal group in HCQ is shielded before the nanoreactor is exposed to tumor-derived proteins. PEGylation can generate a hydration cloud around the nanoreactor to reduce the interaction between the drug and blood components. The inventors used PEGylated lipid membranes to protect the Mal group, which has not been reported before. At the same time, the PEGylated lipid membrane can also prevent the leakage of the drug and further improve the bioavailability of the drug; in addition, the PEGylated lipid membrane makes the nanoreactor have better biocompatibility and can prolong the blood circulation time. Based on this, this embodiment provides an ultrasound-responsive nanoreactor, referred to as Lip@M- M H, comprising a manganese porphyrin-based metal organic framework and a lipid membrane, wherein the manganese porphyrin-based metal organic framework is a carrier, the lipid membrane is coated on the outer surface of the manganese porphyrin-based metal organic framework, and maleimide-modified hydroxychloroquine is loaded on the manganese porphyrin-based metal organic framework.

[0034] Lip@M- M The preparation method of H is different from that of Example 1 in that: M Preparation of HCQ as Lip@M- M Step 1 of the preparation of H, followed by the following two steps:

[0035] Step 2: Preparation of MnTCPP MOF

[0036] 30 mg of zirconium chloride hexahydrate, 0.28 g of benzoic acid and 10.98 mg of porphyrin manganese were dissolved in 14 ml of N,N-dimethylformamide and magnetically stirred at 90°C for 5 hours; after the reaction, the mixture was cooled to room temperature and centrifuged at 15,000 rpm for 15 minutes; the obtained product was washed three times with N,N-dimethylformamide and deionized water, and then resuspended in deionized water to obtain the porphyrin manganese metal organic framework MnTCPP MOF.

[0037] Step 3: Lip@M- M Preparation of H

[0038] S1: 6 mg of dipalmitoylphosphatidylcholine, 2 mg of polyethylene glycol-distearoylphosphatidylethanolamine and 2 mg of cholesterol were dissolved in 5 ml of chloroform, and the mixed solution was transferred to a 100 ml round-bottom flask, and rotary evaporated in a 50-55°C water bath (the water bath temperature in this embodiment is 55°C) to form a lipid film, and then 10 ml of deionized water was added to a beaker to dissolve the lipid film;

[0039] S2: 1 mg MnTCPP MOF was dissolved in a mixed solution of 200 μl N,N-dimethylformamide and 800 μl ultrapure water, and 0.2 mg M HCQ was dispersed in the mixture and magnetically stirred at room temperature for 12 h;

[0040] S3: Then, 2.5 ml of lipid membrane prepared in S1 was added to the mixture of S2, stirred for 3 hours, rinsed with deionized water, and centrifuged at 15000 rpm for 20 minutes to finally obtain the nanoreactor Lip@M- M H.

[0041] Example 3: Lip@M (Lip@M in this application is the abbreviation of lipid membrane@ MnTCPP MOF)

[0042] The difference between Example 3 and Example 2 is that the preparation step of step 1 is omitted, and in step 3 S2, "adding 0.2 mg M HCQ is dispersed in the mixed solution”.

[0043] Comparative Example 1: HCQ

[0044] HCQ was purchased from Shanghai MacLean Biochemical Technology Co., Ltd.

[0045] Comparative Example 2: Lip@MH (Lip@MH in this application is the abbreviation of lipid membrane@ MnTCPP MOF-HCQ)

[0046] The difference between Comparative Example 2 and Example 2 is that the preparation step of step 1 is omitted, and in step 3 S2, 0.2 mg M HCQ is dispersed in the mixed solution. M HCQ was replaced by HCQ.

[0047] 1. Characterization of physical and chemical properties

[0048] (one) M Characterization of HCQ

[0049] This application successfully prepared hydroxychloroquine modified with maleimide group M HCQ. Figure 1 As shown in a, the mass spectrometry results show that the molecular weight of the final product prepared is 487.7 Da, which is close to the theoretical molecular weight of the product. Figure 1 As shown in b, the HPLC results show that the purity of the final product prepared is 95.31%, which indicates that the purity of maleimide-modified hydroxychloroquine is high. Figure 1 c and 1d, the UV-visible spectrum and proton nuclear magnetic resonance hydrogen spectrum confirmed that Example 1 M The chemical structure and absorption maximum of HCQ indicate that the Mal group is successfully coupled to HCQ, wherein Example 1 M The chemical structure of HCQ is Figure 1 d shown in the upper left corner.

[0050] 2. Characterization of MnTCPP MOF

[0051] like Figure 2 As shown in a and 2b, the transmission electron microscopy and scanning electron microscopy results show that the MnTCPP MOF before being wrapped with lipid membrane is spindle-shaped in the solution, evenly dispersed, and has good uniformity. Figure 2 c and 2d, nitrogen adsorption analysis shows that the specific surface area and average pore size of MnTCPP MOF are 1257 m 2 / g and 1.27 nm, indicating that MnTCPP MOF has a mesoporous structure and reliable loading efficiency. Figure 2 As shown in e, the HPLC results show that MnTCPP M The encapsulation efficiency of HCQ was 72.2±7.5%.

[0052] (III) Example 2 Lip@M- M Characterization of H

[0053] The inventors successfully coated the PEGylated lipid membrane on the MnTCPP- M The final nanoreactor Lip@M- MH, to temporarily shield the activity of the nanoreactor. After wrapping the lipid membrane, e.g. Figure 3 As shown in Figure a, a lighter-colored film can be seen on the periphery of MnTCPP in the transmission electron microscope, indicating that the lipid film has been successfully coated on the surface of MnTCPP MOF. Figure 3 As shown in b, elemental analysis shows that oxygen (O), phosphorus (P), zirconium (Zr) and manganese (Mn) are present in the Lip@M- M The distribution of H also further verifies the successful synthesis of the nanoreactor. Figure 3 c and 3d, X-ray diffraction (XRD) and UV-visible spectroscopy data show that MnTCPP and M The performance of HCQ was well preserved in the nanoreactor. Figure 3 As shown in e, the Malvern particle size potential instrument measured that the particle size of the nanoreactor covered with lipid membrane was about 192.93 ± 20.91 nm and the potential was about -16.16 ± 1.34 mv. Figure 3 f, Lip@M- M H was resuspended in various physiological solutions such as deionized water, phosphate buffered saline (PBS), culture medium and physiological saline. The particle size of the nanoreactor did not change significantly, showing good stability. In addition, the inventors studied the release of nanoreactors under ultrasonic irradiation (US) and non-irradiation conditions. M HCQ behavior. Figure 3 As shown in g, about 81% of the drug was released after 48 hours of ultrasound irradiation, which is much higher than the 48% released by nanoparticles without ultrasound irradiation. Figure 3 h, transmission electron microscopy also confirmed the destruction of the lipid membrane, indicating that ultrasonic irradiation of the nanoreactor can decompose the liposome membrane and promote the release of hydroxychloroquine. (The "+US" in the data image of this application indicates that it has been ultrasonically irradiated)

[0054] 2. Ability of MnTCPP to generate ROS

[0055] To evaluate the effect of the nanosystem in inducing SDT, the ability of MnTCPP to generate ROS was verified by electron spin resonance. Figure 4 As shown in a, after ultrasonic irradiation of MnTCPP and Example 3 Lip@M, a typical 1:2:2:1 signal of 5,5-dimethyl-1-pyrroline-n-oxide was observed, proving that hydroxyl radicals (•OH) were captured. However, this characteristic signal was not detected in the MnTCPP and Example 3 Lip@M samples that were not ultrasonically irradiated, as well as the PBS samples that were ultrasonically irradiated. In addition, •OH can gradually degrade methylene blue to change its color from blue to colorless, showing obvious photodegradation characteristics. Figure 4As shown in b, the present application found that only in the MnTCPP + US and Example 3 Lip@M + US sample solutions, the characteristic peak intensity at about 664 nm was significantly reduced, indicating that ultrasound can trigger MnTCPP to produce •OH. In addition, singlet oxygen sensor green (SOSG) was used as a probe to observe the singlet oxygen ( 1 O2) is generated. Figure 4 As shown in Figures 4c and 4d, the fluorescence intensity of the SOSG peak gradually increased with the increase of MnTCPP concentration and the extension of ultrasound irradiation time. These results indicate that MnTCPP and nanosystems containing MnTCPP are sonosensitizers that can produce sonodynamic effects.

[0056] three, M Experiments to prove the effectiveness of HCQ

[0057] Experiment 1: M Autophagy inhibition efficiency of HCQ

[0058] In order to verify the enhanced autophagy blocking mechanism based on click chemistry, the evaluation of Example 1 M The present invention conducted a series of verification experiments to test the anti-autophagic efficiency of HCQ. The exposed Mal group can capture tumor proteins by reacting with -SH. Figure 5 As shown in a, ovalbumin (OVA) containing free SH groups was used to simulate damaged tumor-derived proteins in vitro. Figure 5 c, the inventors found that M The zeta potential of OVA incubated with HCQ increased from -23.0 mV to -12.4 mV, while the zeta potential of OVA incubated with HCQ in comparative example 1 did not change significantly, indicating that after incubation, M HCQ has been anchored to the protein. In addition, the present application also studied the reaction between the nanoreactor and OVA before and after ultrasonic treatment, such as Figure 5 As shown in d, the ultrasonically treated Lip@M- M The zeta potential of oocytes incubated with H is similar to that of Example 1 M The trend of HCQ is similar; while in Example 2, Lip@M- M There was no significant change in the group without ultrasound. This is because the PEGylated coating will prevent the reaction to a certain extent, but ultrasound can remove the coating to restore M Reactivity of HCQ.

[0059] In addition, the present application prepared cell fragments and transwell devices to further verify the above theory. Figure 5 As shown in b, different drug preparations were placed in the lower transwell chamber, and cell fragments were placed in the upper chamber. Figure 5As shown in e and 5f, after incubation for 24 h, Example 1 M The amount of lower cavity protein in HCQ is greater than that in HCQ of Comparative Example 1, while that in Example 1 M The amount of protein residue in the upper cavity of HCQ was less than that of HCQ in comparative example 1. These results indicate that maleimide-functionalized hydroxychloroquine can be M Based on the fact that HCQ can bind more cell debris than HCQ, the present invention then evaluated the M The autophagy inhibition efficiency of HCQ. LC3B dots are associated with the formation of autophagosomes, and the immunofluorescence images of LC3B dots were shown using CLSM. Figure 5 k shows that compared with the comparative example 2 Lip@MH + US, the Lip@M- M More green LC3B puncta appeared in H + US, which was due to more blocked autophagosomes. Figure 5 As shown in gj, Western blotting also showed that autophagy-related proteins LC3B-II / I and beclin-1 were expressed in Lip@M- M The p62 content in the H + US group was upregulated, indicating that the autophagy process began after SDT activation. More importantly, compared with other control examples, the p62 content in Example 2 Lip@M- M p62, an autophagic substrate, was recruited to and degraded in the autophagosome, even though autophagy had already been initiated. This suggests that the nanoreactor interferes with the integrated autophagic process, leading to the accumulation of autophagic substrates. Bio-TEM was used to directly observe autophagic vesicles in cells, such as Figure 5 As shown in i, Example 2 Lip@M- M After H + US treatment, a large number of autolysosomes encapsulating the nanoreactors could be observed in 4T1 cells.

[0060] In summary, compared with HCQ in comparative example 1, due to click chemistry-mediated autophagy capture, the above results confirm that M HCQ can better inhibit the autophagy process induced by SDT.

[0061] Experiment 2: In vitro cytotoxicity studies

[0062] This application evaluates the biosafety of nanomaterials, e.g. Figure 6 As shown in a, different concentrations of Example 2 Lip@M- M After incubation with 5% H, the cell survival rate was higher than 80%.

[0063] The combined efficacy of SDT and autophagy blockers was further investigated by cell viability assessment. Figure 6As shown in c, the comparative example 2 Lip@MH + US activation treatment showed good cytotoxicity, indicating that there is a synergistic effect between SDT and autophagy blocking strategy; compared with the comparative example 2 Lip@MH + US, the example 2 Lip@M- M The cell viability of H + US dropped sharply to below 20%, indicating that the efficiency of autophagy blocking was significantly improved, and SDT-induced cell apoptosis could be further enhanced, thereby inhibiting the growth of cancer cells. In addition, flow cytometry apoptosis quantitative analysis also confirmed these results, such as Figure 6 d and 6e, similar to the results of the cytotoxicity experiment, compared with the comparative example 2 Lip@MH + US, the example 2 Lip@M- M The percentage of tumor cell apoptosis is higher after H + US treatment. The present invention also uses calcein-AM and propidium iodide (PI) fluorescent dyes to visually observe dead cells and live cells. Figure 6 f, the experimental results show that compared with the comparative example 2 Lip@MH + US, the example 2 Lip@M- M The red fluorescence emitted by H + US apoptotic cells is stronger, indicating that Example 2 Lip@M- M H + US causes greater damage to cells.

[0064] Experiment 3: Biosafety Testing

[0065] In order to determine the short-term and long-term biosafety of the nanoreactor, the present application conducted a hemolysis test. Figure 7 As shown in Figure 1, the inventors found that the hemolysis rate of MnTCPP in comparative example 3 was slightly higher, but after being wrapped by the lipid membrane, the hemolysis rate dropped from more than 5% to 2.82%, indicating that its biocompatibility was improved. M H Routine blood tests and blood biochemical indicators after 1, 3, 7, 14, and 28 days. Figure 7 As shown in bm, no obvious abnormalities were found compared with the control group, indicating no obvious systemic toxicity. Figure 7 As shown in Figure 1, H&E staining of major organs showed no abnormal inflammatory response or histopathological changes in either the short or long term. These results clearly demonstrate that the multifunctional nanoreactor has good biosafety in vivo, paving the way for future clinical transformation.

[0066] The above is only an embodiment of the present invention, and the common knowledge such as the known specific technical solutions and / or characteristics in the solution is not described in detail here. It should be pointed out that for those skilled in the art, without departing from the technical solution of the present invention, several modifications and improvements can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicality of the patent. The scope of protection required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.

Claims

1. A maleimide-modified hydroxychloroquine, characterized in that The compound has the structure shown below: 。 2. The method for preparing maleimide-modified hydroxychloroquine according to claim 1, wherein The steps include: Hydroxychloroquine is dissolved in N,N-dimethylformamide, and then the solution is mixed with 3-maleimidopropionic acid, 4-dimethylaminopyridine, 1-hydroxybenzotriazole and carbodiimide, and then stirred. After spin drying, maleimide-modified hydroxychloroquine is obtained, and finally purified.

3. The method for preparing maleimide-modified hydroxychloroquine as claimed in claim 2, wherein The stirring time is 6-8 hours.

4. The method for preparing maleimide-modified hydroxychloroquine as claimed in claim 3, wherein Purification was performed using high performance liquid chromatography.

5. The method for preparing maleimide-modified hydroxychloroquine as claimed in claim 4, wherein The mass ratio of hydroxychloroquine to 3-maleimidopropionic acid is 4:2405.

6. Use of the maleimide-modified hydroxychloroquine according to claim 1 in preparing a drug for treating tumors.

7. The use according to claim 6, characterized in that The tumor is breast cancer.

8. The use according to claim 6, characterized in that Maleimide-modified hydroxychloroquine is loaded on the carrier.

9. The use according to claim 8, characterized in that The carrier is a manganese porphyrin-based metal organic framework.

10. The use according to claim 9, characterized in that The manganese porphyrin-based metal organic framework is in the shape of a shuttle.